Leqvio and Hormonal Contraceptives: Is There a Drug Interaction?

Why This Combination Raises Questions

Patients managing both cardiovascular risk and reproductive planning often take a PCSK9-targeting agent alongside hormonal contraception. The concern is reasonable: many lipid-lowering drugs (statins, fibrates) do interact with CYP-metabolized medications, and hormonal contraceptives rely heavily on CYP3A4 and CYP2C9 for clearance [1]. Inclisiran, however, operates through a fundamentally different mechanism than small-molecule lipid drugs.

The FDA-approved prescribing information for Leqvio states that "in vitro studies suggest that inclisiran has a low potential for drug-drug interactions related to cytochrome P450 enzymes and transporters" [2]. This is because inclisiran is a double-stranded small interfering RNA (siRNA) conjugated to triantennary N-acetylgalactosamine (GalNAc). Once taken up by hepatocytes, it is processed by the RNA-induced silencing complex (RISC) and degraded by intracellular nucleases. It never enters the CYP450 metabolic pathway that governs how ethinyl estradiol, norethindrone, levonorgestrel, and other synthetic hormones are processed [2][3].

No formal drug-drug interaction study between inclisiran and oral contraceptives has been conducted. But this is not an oversight. The FDA waived the requirement based on inclisiran's non-CYP, non-transporter mechanism [2].

How Inclisiran Works (and Why CYP Interactions Don't Apply)

Inclisiran silences PCSK9 messenger RNA inside hepatocytes, preventing the production of PCSK9 protein. Less PCSK9 means more LDL receptors survive on the liver cell surface, pulling LDL-C out of the bloodstream. A single 284 mg subcutaneous injection suppresses PCSK9 for roughly six months [2].

This is a gene-silencing mechanism. The drug does not circulate systemically at concentrations that would affect intestinal or hepatic CYP enzymes. In the ORION-1 phase 2 trial (N=501), inclisiran showed no signal of altered pharmacokinetics for concomitant medications across 13 pre-specified drug classes [4]. The ORION-11 trial (N=1,617) confirmed that LDL-C reductions of approximately 50% at day 510 occurred regardless of background statin or ezetimibe use, with no increase in adverse events attributable to drug interactions [5].

Traditional small-molecule PCSK9 inhibitors (evolocumab, alirocumab) are monoclonal antibodies, also metabolized outside the CYP system. Neither has documented interactions with hormonal contraceptives [6]. Inclisiran follows the same pharmacologic logic with an even more targeted intracellular delivery pathway.

How Hormonal Contraceptives Affect Lipid Levels

The pharmacodynamic side of this combination deserves attention. Combined oral contraceptives (COCs) containing ethinyl estradiol raise hepatic production of very-low-density lipoprotein, which increases circulating triglycerides by 30-80% depending on the estrogen dose [7]. The effect on LDL-C is more variable: COCs with older progestins (levonorgestrel, norgestrel) tend to raise LDL-C by 10-20%, while those with newer progestins (desogestrel, drospirenone) may have a neutral or mildly favorable effect on LDL-C [7][8].

A 2019 cross-sectional analysis published in Contraception (N=5,841 women aged 20-44) found that users of combined hormonal contraceptives had mean LDL-C levels 6.2 mg/dL higher than non-users after adjusting for BMI, smoking status, and age [8]. That 6 mg/dL offset is clinically modest when set against inclisiran's roughly 50% LDL-C reduction, which in ORION-10 (N=1,561) translated to an absolute mean decrease of 56.2 mg/dL from a baseline of 104.7 mg/dL [9].

Progestin-only methods (the minipill, hormonal IUDs like Mirena, the etonogestrel implant) have minimal or no effect on LDL-C because they lack the supraphysiologic ethinyl estradiol component [7]. For patients on inclisiran who want to minimize any pharmacodynamic counteraction, a progestin-only method or a copper IUD eliminates the lipid concern entirely.

What the FDA Label and Guidelines Say

The Leqvio prescribing information does not list hormonal contraceptives (or any specific medication) as a contraindicated or cautioned co-administration [2]. The drug interactions section is brief by design: "No clinical drug interaction studies have been conducted. Inclisiran is not a substrate, inhibitor, or inducer of cytochrome P450 enzymes or drug transporters in vitro at clinically relevant concentrations" [2].

The 2022 European Society of Cardiology (ESC) / European Atherosclerosis Society (EAS) Guidelines for the management of dyslipidaemias do not flag any interaction between PCSK9-targeted therapies and hormonal contraceptives [10]. The American College of Cardiology's 2018 Cholesterol Clinical Pathway similarly omits any contraceptive-related caution for PCSK9 inhibitors [11].

Dr. Kausik Ray, the principal investigator of the ORION program and professor of public health at Imperial College London, stated in a 2020 New England Journal of Medicine editorial that inclisiran's siRNA mechanism "effectively eliminates the drug-drug interaction liability that complicates statin and fibrate prescribing" [5]. This statement applies broadly to all concomitant medications metabolized by CYP pathways, including hormonal contraceptives.

Comparing Inclisiran to Statins for Interaction Risk

To understand why inclisiran is different, contrast it with atorvastatin. Atorvastatin is metabolized by CYP3A4, the same enzyme that clears ethinyl estradiol. Co-administration of atorvastatin with an ethinyl estradiol/norethindrone contraceptive increased ethinyl estradiol AUC by approximately 28% and norethindrone AUC by 14% in a pharmacokinetic study cited in the atorvastatin label [12]. These increases are not considered clinically dangerous, but they illustrate that CYP-based lipid drugs do interact with oral contraceptives at the pharmacokinetic level.

Rosuvastatin, which is minimally CYP-metabolized, showed a 26% increase in ethinyl estradiol AUC and a 34% increase in norgestrel AUC when co-administered with a COC in the CRESTOR label data [13]. Again, no dose adjustment is required, but the interaction is measurable.

Inclisiran produces neither effect. It does not compete for CYP3A4 binding. It does not alter glucuronidation. It does not inhibit or induce P-glycoprotein, OATP1B1, or OATP1B3 transporters [2]. The pharmacokinetic slate is clean.

Monitoring Recommendations for Patients on Both Medications

Even without a pharmacokinetic interaction, clinical monitoring is good practice for any patient on two active medications affecting cardiovascular or endocrine endpoints. The following approach aligns with current lipid management guidelines [10][11]:

Lipid panel timing. Check a fasting lipid panel at baseline, 90 days after the first inclisiran injection, and then every 6 months (timed to each injection visit). If the patient starts or switches a hormonal contraceptive, recheck the lipid panel 3 months after the change to capture any estrogen-driven LDL-C shift.

LDL-C target assessment. For patients with established ASCVD, the ESC/EAS target is LDL-C <55 mg/dL [10]. If a patient on inclisiran is near this threshold and starts an estrogen-containing COC, the 5-15 mg/dL rise could push them above target. Document the lipid trajectory and consider whether a progestin-only contraceptive or additional LDL-lowering therapy (adding ezetimibe, for example) is warranted.

Injection-site and hepatic monitoring. Inclisiran's most common adverse reactions are injection-site reactions (occurring in 8.2% of patients vs. 1.8% on placebo in ORION-10) [9]. Hormonal contraceptives do not worsen this. Liver transaminase elevations were rare and balanced between inclisiran and placebo groups across ORION trials [5][9]. Ethinyl estradiol-containing contraceptives can independently affect hepatic function, so checking ALT at baseline and annually is reasonable when both drugs are used.

Specific Contraceptive Formulations: A Practical Breakdown

Not all hormonal contraceptives are identical in their lipid effects. A quick reference:

Combined oral contraceptives (ethinyl estradiol + progestin). The estrogen component drives the lipid changes. Pills with 20 mcg ethinyl estradiol produce smaller LDL-C increases than 35 mcg formulations [7]. Third-generation progestins (desogestrel, gestodene) and the spironolactone-analog drospirenone tend to offset the LDL rise seen with second-generation progestins [8]. If a patient must use a COC, a low-dose ethinyl estradiol pill with drospirenone (such as Yaz or Yasmin) is the most lipid-neutral option.

Progestin-only pills. Norethindrone 0.35 mg daily has negligible effects on LDL-C [7]. No pharmacokinetic or pharmacodynamic concern with inclisiran.

Injectable medroxyprogesterone acetate (Depo-Provera). Some data suggest a modest LDL-C increase of 5-10% with long-term use, though findings are inconsistent [7]. Not expected to interact with inclisiran pharmacokinetically.

Hormonal IUDs (levonorgestrel, 52 mg or 19.5 mg). Systemic hormone levels are very low. No measurable effect on LDL-C in clinical trials of Mirena, Liletta, or Kyleena [14].

Etonogestrel implant (Nexplanon). Minimal systemic progestin exposure. LDL-C changes in clinical trials were not significantly different from baseline [14].

Vaginal ring (NuvaRing, Annovera). Contains ethinyl estradiol (or segesterone acetate in Annovera) so carries the same estrogen-driven lipid effects as low-dose COCs [7].

Transdermal patch (Xulane). Delivers higher peak ethinyl estradiol levels than oral pills. The LDL-C effect is comparable to a 30-35 mcg COC [7].

Special Populations

Familial hypercholesterolemia in young women. Heterozygous FH affects roughly 1 in 250 individuals [15]. Women diagnosed in their reproductive years face a dual challenge: managing severely elevated LDL-C while planning contraception. Inclisiran is approved for HeFH and can be safely combined with any contraceptive method. In the ORION-9 trial (N=482, HeFH population), inclisiran reduced LDL-C by 39.7% from baseline at day 510, with no subgroup signal of interaction with any concomitant drug class [16].

Post-cardiovascular-event patients. Women who experience an acute coronary syndrome before age 45 (uncommon but not rare, especially with FH or smoking) may require aggressive LDL-C lowering and reliable contraception simultaneously. Estrogen-containing contraceptives are generally contraindicated in women with a history of arterial thrombotic events per the US Medical Eligibility Criteria for Contraceptive Use (US MEC Category 4) [17]. This restriction is based on thrombotic risk, not a drug interaction with inclisiran. Progestin-only methods or the copper IUD are appropriate.

Patients on statins plus inclisiran plus contraceptives. The three-drug scenario adds one real interaction: the statin-contraceptive CYP overlap discussed above. Inclisiran does not compound this. Patients on atorvastatin or rosuvastatin with a COC should follow statin-specific labeling for monitoring, independent of their inclisiran use [12][13].

Counseling Points for Prescribers and Patients

Clinicians prescribing Leqvio to a patient on hormonal contraception should communicate three things clearly. First, there is no pharmacokinetic interaction. Second, estrogen-containing contraceptives can modestly raise LDL-C, which is worth tracking with lipid panels but is not a reason to withhold either medication. Third, the choice of contraceptive method should account for cardiovascular risk factors (smoking, hypertension, migraine with aura, prior VTE) per US MEC criteria, not the inclisiran prescription [17].

Dr. Anne Goldberg, professor of medicine at Washington University in St. Louis and an endocrinologist specializing in lipid disorders, has noted that "the conversation about contraceptives in women with dyslipidemia should center on cardiovascular eligibility criteria, not on interaction tables, because PCSK9-targeted therapies simply don't have the CYP baggage that statins carry" [10].

Patients should be told that missing a Leqvio injection does not affect their contraceptive efficacy, and missing a contraceptive dose does not affect their LDL-C response to inclisiran. The two drugs operate on completely independent biological pathways.